ViiV Healthcare presents a new podcast about the Power of Being Seen

ViiV Healthcare announces its new weekly podcast Being Seen an in-depth exploration of the role culture plays in resolving how we see ourselves and how we are seen by others. Hosted and narrated by Darnell Moore award-winning writer and activist, the first season explores current cultural representations of the queer and gay Black male experience and the impact on their lives and society. Being Seen is available October 6 th wherever you get your podcasts and at www.beingseenpodcast.com .

Through conversations with leading artists, writers, activists, entertainers, and community leaders including; writer, director, and producer Lee Daniels and Ben Cory Jones ; Samira Nasr , Editor-in-Chief at Harper's Bazaar, and activist, writer, George M. Johnson , ViiV Healthcare hopes Being Seen encourages the creation of more accurate cultural portrayals of the queer and gay Black male experience in order to reduce stigma and change perception - impacting everything from HIV to institutional inequality.

"There is nothing else like Being Seen in the podcast universe for Black gay and queer men – it's a safe space and platform for them to express themselves, share their experiences, and bare their souls and identities freely and uncensored," said Marc Meachem , head of US External Affairs for ViiV Healthcare.  "We think it will reduce stigma and bring hope to Black gay and queer men who may find their story in the stories being shared on the podcast and know they are not alone, they are being seen – and we hope it encourages them to write or tell their own story even if it's just for themselves."

The project has been enriched and informed by creative consultants and partners Emil Wilbekin founder of Native Son; DaShawn Usher founder of MOBI; Emmy winning producer Darius Brown ; Photographers Gioncarlo Valentine and Texas Isaiah – both of whom served as curators for Being Seen photography. As well as the incredible group of illustrators and photographers who either licensed work or created original work to help bring the project to life visually and through sound.  Theme music for the podcast is Colouour by Moses Sumney .

"Being Seen podcast is another medium through which the lives of Black queer and trans men are uplifted and centered. Our contributions to culture matter. The work that so many of us do on behalf Black people matters" said Darnell Moore . "And we have to share our stories, as different and complex as they may be, to push back against the erasure of our work and voices. I hope that audiences end every episode a bit more committed to co-creating a world where the lives of all Black people matter."

ViiV's evolving commitments to communities in the US most disproportionately impacted by HIV, and the reality of current times have motivated support of this new cultural collaboration.

"Our sole focus on HIV and the HIV community for more than 10 years has given ViiV clear insights into the importance of listening and hearing the community – and we are committed to amplifying those voices through our work" said Lynn Baxter , Head of North America , ViiV Healthcare. " Being Seen brings awareness to the impact of stigma on every aspect of these individual's lives and spotlights the obligation everyone has to end discrimination against marginalized communities, including people living with HIV."

Being Seen expands on the insights and findings from landmark ethnographic research conducted by ViiV Healthcare, exploring the lives of Black gay men in Baltimore, Maryland , and Jackson, Mississippi.  This research uncovered that these men wanted the freedom to create their own experiences and live without labels. It also gave life to the ground-breaking experiential theater piece As Much As I Can , created and produced by Harley & Co and presented by ViiV Healthcare.

Being Seen is produced by Harley & Co. and Darnell Moore and created in partnership with ViiV Healthcare.

Artwork by Ronald Jackson

About Darnell Moore – Being Seen host and producer

Darnell L. Moore is an award-winning writer, activist, organizer, and author of No Ashes in the Fire: Coming of Age Black and Free in America. He is Director of Inclusion Strategy for Content & Marketing at Netflix, editor-at-large at CASSIUS and co-managing editor at The Feminist Wire. A prolific writer, Darnell has been published in various media outlets including MSNBC, The Guardian, Huffington Post, EBONY, The Root, The Advocate, OUT Magazine, VICE and others, as well as numerous academic journals. He received the Humanitarian Award from the American Conference on Diversity for his LGBTQ advocacy and has been named among EBONY Magazine's Power 100, Time Out New York's Eight LGBT Influencers, The Root 100, and Planned Parenthood's Top 99 Dream Keepers.

About Harley & Co – Being Seen Producer

Harley & Co. is a New York based creative studio that produces award-winning multi-platform social justice and culture projects such as activist experiential theater, "As Much As I Can." Their work has won numerous awards including Cannes Lions, AD&D, Shorty for Social Good and most recently, Fast Company's World Changing Ideas. Harley & Co. has been featured in the NYTimes, Teen Vogue, NBC, ABC and Bloomberg, among others, for their unique creative design and approach.

About ViiV Healthcare

ViiV Healthcare is the only pharmaceutical company solely focused on combating, preventing, and ultimately curing HIV and AIDS.  We exist to make sure no one living with HIV and AIDS is left behind, and we are 100% dedicated to addressing the challenges of the HIV epidemic. Our portfolio ambition is to make HIV a smaller part of people lives.  Beyond developing innovative medicines, ViiV Healthcare works with communities to address enduring disparities in HIV care and outcomes.

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012 . The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline and commitment, please visit https://viivhealthcare.com/en-gb/ .

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com .

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK's Principal risks and uncertainties section of the Q2 Results and any impacts of the COVID-19 pandemic.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/viiv-healthcare-presents-a-new-podcast-about-the-power-of-being-seen-301143992.html

SOURCE ViiV Healthcare

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

New Novartis Fabhalta® data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy

  • APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1

  • IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide 2 ; complement activation is a key driver of glomerular inflammation in IgAN 3,4

  • There is a need for effective, targeted therapies for IgAN 2,5 ; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure within 10 years, requiring maintenance dialysis and/or kidney transplantation 6

  • Novartis continues to advance broad renal portfolio in late-stage development, exploring the potential to slow disease progression and extend dialysis-free life

Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta ® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN) 1 . In the analysis, patients treated with Fabhalta achieved a 38.3% (p

Proteinuria reduction is an increasingly recognized surrogate marker correlating with progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated approvals 7 . The study also showed that Fabhalta was well tolerated with a favorable safety profile consistent with previously reported data 1,8 . Results were presented today during a late-breaking clinical trials session at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina 1 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –

– Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New Novartis data show early addition of twice-yearly* Leqvio® following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

  • V- INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively) 1
  • A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment 1
  • Results from usual care arm reinforce the urgent need for more aggressive LDL-C lowering in ASCVD patients, 92% of whom did not reach their LDL-C goal with statins alone 1
  • The Leqvio safety profile was consistent with the Phase III clinical studies and long-term open-label extension trials for up to 6 years of treatment 1-4

Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone 1 . The late-breaking data were presented at the 2024 American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology .

"V-INITIATE evaluated a solution to the important challenge seen in clinical practice of too many patients with ASCVD not achieving guideline-recommended LDL-C goal on statins alone and effective non-statin therapies being markedly underutilized," said Michael Koren , M.D., Medical Director and CEO of Jacksonville Center for Clinical Research, and the primary investigator of the study. "Given the urgent need to more aggressively manage LDL-C, the results from V-INITIATE show that when added earlier in the treatment continuum, the structured use of effective non-statin therapies like Leqvio can significantly reduce LDL-C for ASCVD patients who are struggling to reach or maintain their LDL-C goal."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRxâ„¢ in patients with
recurrent pericarditis, with topline results expected in Q2 2024

CardiolRxâ„¢ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,
which includes recurrent pericarditis

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Jamieson Wellness Publishes Inaugural Sustainability Impact Report

From values to action, the Company details progress towards its sustainability commitments in its "Inspiring Better Lives Every Day: 2023 Sustainability Impact Report"

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today announces the release of its "Inspiring Better Lives Every Day: 2023 Sustainability Impact Report". The comprehensive report underscores the Company's commitment to creating a sustainable future while aligning with its core values of Respect, Excellence, Accountability, and Agility. The Company's new purpose, "Inspiring Better Lives Every Day," serves as its guiding light as it navigates the path toward positive impact.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Pills spilling out of a pill bottle on a yellow background.

Pharma Stocks: 5 Biggest Companies in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less

Latest Press Releases

Related News

×